Burning Rock Biotech (BNR) EBT Margin (2019 - 2026)

Burning Rock Biotech (BNR) has reported EBT Margin for 8 consecutive years, with 15.96% the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT Margin fell 598.0% year-over-year to 15.96%; the TTM figure through Mar 2026 stood at 11.27% (up 3302.0% YoY), while the FY2025 annual figure was 9.97%, up 5609.0% from the prior year.
• EBT Margin came in at 15.96% for Q1 2026 at Burning Rock Biotech, down from 11.48% in the prior quarter.
• The five-year high for EBT Margin was 6.37% in Q2 2025, with the low at 200.29% in Q2 2022.
• Average EBT Margin over 5 years is 88.41%, with a median of 89.42% recorded in 2023.
• Across the five-year window, EBT Margin plunged 4155 bps in 2022 and jumped 11087 bps in 2023, its largest moves.
• Year by year, EBT Margin stood at 150.68% in 2022, then increased by 12 bps to 133.09% in 2023, then surged by 55 bps to 60.29% in 2024, then surged by 81 bps to 11.48% in 2025, then plunged by 39 bps to 15.96% in 2026.
• According to Business Quant data, EBT Margin over the past three periods registered 15.96%, 11.48%, and 12.58% for Q1 2026, Q4 2025, and Q3 2025 respectively.